美沙拉嗪及柳氮磺砒啶在治疗溃疡性结肠炎中的对比分析

目的：观察比较美沙拉嗪及柳氮磺砒啶治疗溃疡性结肠炎的临床疗效及其安全性。方法：提取2008年5月-2013年3月在本院治疗的50例溃疡性结肠炎患者的临床资料,其中25例运用美沙拉嗪治疗,设为观察组,另外25例运用柳氮磺砒啶治疗,设为对照组。比较两组患者治疗后的腹泻、腹痛、黏液血便等临床症状改善情况,评价并比较治疗后两组患者临床总有效率,观察比较两组患者治疗过程中不良反应发生情况。结果：治疗后两组的腹泻评分、腹痛评分、黏液血便评分均优于治疗前,比较差异有统计学意义（P<0.05）;观察组治疗后的腹泻评分、腹痛评分、黏液血便评分均优于对照组治疗后,观察组临床症状改善程度优于对照组,比较差异有统计学意义（P<0.05）;治疗后观察组总有效率为84.00%（21/25）,对照组总有效率为68.00%（17/25）,观察组优于对照组,比较差异有统计学意义（P<0.05）;治疗过程中观察组并发症发生率为12%（3/25）,对照组并发症发生率为48.00%（12/25）,观察组并发症发生率优于对照组,比较差异有统计学意义（P<0.05）。结论：美沙拉嗪及柳氮磺砒啶治疗溃疡性结肠炎都能明显改善患者的临床症状,但是美沙拉嗪有效率和安全性更高,更能显著的改善患者的临床症状,可优先选择使用。     

HPLC荧光法测定人血浆中的5-氨基水杨酸

目的 采用HPLC荧光法测定人血浆中的5-氨基水杨酸,研究单剂量口服柳氮磺吡啶肠溶片后5-氨基水杨酸在中国健康受试者体内的药动学特征.方法 24名健康受试者口服500 mg柳氮磺吡啶肠溶片,采用HPLC荧光法测定血浆中5-氨基水杨酸的浓度,利用DAS 2.1.1软件计算药动学参数.结果 5.055～808.8 ng·mL-1 5-氨基水杨酸与峰面积比值的线性关系良好(r =0.9985),最低检测浓度为5.055 ng· mL-1,日内、日间RSD均＜10％.单次口服给药后,药动学参数为:t1/2=11.19 _±2.48 h,Cmax=232.83±57.94 ng· mL-1,Tmax =17.58 ±5.33 h,AUC(0～t)=5.5907±1.7848 μg·h·mL-1.结论 所用方法准确、灵敏度高、重复性好,可用于口服柳氮磺吡啶肠溶片后5-氨基水杨酸血药浓度测定及人体药动学研究.     

The influence of probiotic treatment on sulfasalazine metabolism in rat

1. Probiotics are live microorganisms claimed to exert beneficial effects on the host. This study investigated their effect on the metabolism and pharmacokinetics of sulfasalazine (SSZ), a drug whose efficacy depends on metabolism by azoreductase (AR) in the gut microbiota to sulfapyridine (SP) and 5-acetylsalicylic acid (5-ASA).

2. The probiotic strains Lactobacillus acidophilus L10, Bifidobacterium lactis B94 and Streptococcus salivarius K12 possessed AR activity and a corresponding ability to metabolize SSZ.

3. Treatment of male Wistar rats (n = 5) with oral 2 g doses of a mixture of the three probiotics (total dose 1.8 × 10⁹ cfu) every 12 h for 3 days resulted in a significant increase (p < 0.05) in AR activity in ex vivo colon contents with a corresponding increase in SSZ metabolism.

4. Similar probiotic treatment of male Wistar rats (n = 8) followed by an oral 100 mg/kg dose of SSZ produced high plasma levels of SP, but pharmacokinetic parameters of SSZ and SP were not significantly different from control rats given SSZ.

5. These results indicate that probiotic strains possess AR activity and can metabolize SSZ. Treatment with probiotics increases AR activity in the gut microbiota but has no effect on plasma levels of SSZ and SP following a subsequent oral dose of SSZ.

     

中西医结合治疗溃疡性结肠炎的临床研究

目的评价中西医结合治疗溃疡性结肠炎的疗效。方法将90例溃疡性结肠炎患者分为对照组和观察组。对照组：柳氮磺胺吡啶片口服,注射用氢化可的松琥珀酸钠加生理盐水作保留灌肠;观察组：在对照组用药方式的基础上,加用中药方剂保留灌肠,同时口服中药汤剂。结果观察组显效率73．33％（33／45）高于对照组显效率48．89％（22／45）,差异具有显著性（P〈0．05）;观察组总有效率100．00％（45／45）高于对照组总有效率86．67％（39／45）,差异具有显著性（P〈0．05）。两组均未见明显不良反应。结论中西医结合治疗溃疡性结肠炎疗效可靠,安全性高。     

来氟米特联合甲氨蝶呤治疗类风湿性关节炎的疗效观察

目的：观察来氟米特联合甲氨蝶呤治疗类风湿性关节炎的疗效。方法：选取我院于2009年10月～2010年1月所收治的98例类风湿关节炎患者,随机分为两组。对照组49例,采用甲氨蝶呤与柳氮磺胺吡啶治疗类风湿性关节炎。治疗组49例,采用来氟米特与甲氨蝶呤进行治疗。结果：采用甲氨蝶呤与柳氮磺胺吡啶治疗6个月总有效率为71.4%。采用来氟米特与甲氨蝶呤治疗6个月,总有效率为89.8%。结论：采用来氟米特与甲氨蝶呤可以安全有效地治疗类风湿性关节炎。     

中西医药物治疗溃疡性直肠炎的临床疗效观察

目的:探讨中西医药物治疗溃疡性直肠炎的临床疗效.方法:175例患者随机分为两组,治疗组采用中药保留灌肠,对照组用柳氮磺胺吡啶(SASP)肛栓剂塞肛.结果:治疗组的完全缓解、总有效率均明显优于对照组(p＜0.01);随访8个月及12个月,治疗组的复发率与对照组相比,差异有统计学意义(p＜0.05).结论:中药保留灌肠治疗...     

The treatment of ankylosing spondylitis

Ankylosing spondylitis is an inflammatory disorder affecting the axial skeleton and periphery. Symptoms can often be debilitating. Current therapy for the disease include physical therapy, non-steroidal anti-inflammatory drugs (NSAIDS, anti-rheumatic disease modifying drugs (DMARDS), and the newly developed biologic agents targeting tumor necrosis factor alpha (TNF-α). This paper will provide a comprehensive review of these treatments which focusing on evidence based medicine for the daily clinical practice of rheumatology. Received: 31 December 2002 / Accepted: 15 January 2003 Correspondence to J.C. Davis Jr.     

Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases

Heart involvement – often asymptomatic – is largely underestimated in patients with systemic autoimmune diseases (SADs). Cardiovascular events are more frequent in patients with SADs compared to the general population, owing to the consequences of inflammation and autoimmunity and to the high prevalence of traditional risk factors. Coronary microvascular disease (CMD) is a form of cardiac involvement that is increasingly recognised yet still largely neglected. CMD, the incapacity of the coronary microvascular tree to dilate when myocardial oxygen demand increases or when there is a microvascular spasm (or subclinical myocarditis), is increasingly reported because of the widespread use of new cardiac imaging tools, even in a subclinical phase. The assessment of myocardial coronary flow reserve (CFR) emerged as the most effective clinical tool to detect microvascular damage. The potential causes of microvascular damage, molecular and cellular inflammation along with a pathological CD39-CD73 axis, need always to be considered because data show that they play a role in the occurrence of acute coronary syndromes, heart failure and arrhythmias, even in the early asymptomatic stage. Data suggest that controlling disease activity by means of methotrexate, biologic drugs, antimalarial medications, statins and aspirin, according to indication, might reduce the cardiovascular risk related to macrovascular and microvascular damage in most patients with SADs, provided that they are used early and timely to control diseases. The need of new biomarkers and a careful assessment of myocardial CFR emerged as the most effective clinical tool to detect microvascular damage.     

腐殖酸钠保留灌肠治疗轻中度溃疡性结肠炎

目的:观察腐殖酸钠(SHA)保留灌肠治疗活动期的轻中度溃疡性结肠炎(UC)的疗效和副作用。方法:采用与柳氮磺胺吡啶(SASP)对照方法进行分析,以活动指数进行临床分级来评价疗效。结果:SASP缓解率为92.86%,SHA达93.75％,两者无显著差异。结论:SHA治疗活动期的轻中度UC有较高的疗效,且价谦,无明显副作用。     

Sulfasalazine Induces Autophagic Cell Death in Oral Cancer Cells via Akt and ERK Pathways

Sulfasalazine (SSZ) is an anti-inflammatory drug that has been used to treat inflammatory bowel disease and rheumatoid arthritis for decades. Recently, some reports have suggested that SSZ also has anti-cancer properties against human tumors. However, little is known about the effects of SSZ on oral cancer. The aim of this study was to investigate the anti-cancer effects of SSZ in oral squamous cell carcinoma (OSCC) cells and to elucidate the mechanisms involved. The authors investigated the anti-proliferative effect of SSZ using the MTT method in HSC-4 cells (an OSCC cell line). Cell cycle analysis, acidic vesicular organelle (AVO) staining, monodansylcadaverine (MDC) staining and Western blotting were also conducted to investigate the cytotoxic mechanism of SSZ. SSZ significantly inhibited the proliferation of HSC-4 cells in a dose-dependent manner. In addition, SSZ induced autophagic cell death, increased microtubule-associated protein 1 light chain (MAP1-LC; also known as LC) 3-II levels, as well as induced punctate AVO and MDC staining, resulted in autophagic cell death. Furthermore, these observations were accompanied by the inhibition of the Akt pathway and theactivation of ERK pathway. These results suggest that SSZ promotes autophagic cell death via Akt and ERK pathways and has chemotherapeutic potential for the treatment of oral cancer.